backgroundGraphic
heroImageheroImage

On-demand Sessions

We bring you exclusive sessions from our scientific workshops, featuring roundtable discussions with world-leading experts.

Each session focuses on a key topic aligned with the workshop program.

heroImageheroImage

Explore roundtable discussions from our scientific workshops

  • iwMDS

    Novel targets in MDS: telomerase inhibition, the SELECT-MDS-1 trial, PK agonists, & more

    iwMDS 2025

    27 - 29 June, 2025

  • iwMDS

    Evolving strategies in clinical trial design for MDS: defining response criteria

    iwMDS 2025

    27 - 29 June, 2025

  • iwMDS

    iwMDS wrap-up: translating research into practice to optimize patient care

    iwMDS 2025

    27 - 29 June, 2025

  • iwMDS

    Advances made in MDS classification and risk stratification: ongoing work & future perspectives

    iwMDS 2025

    27 - 29 June, 2025

  • iwMPN

    Novel therapeutic approaches in MPNs: targeting CALR, immune modulation, & JAKi specificity

    iwMPN 2025

    27 - 29 June, 2025

  • iwMPN

    Challenges of managing blast-phase MPNs: the role of transplant, impact of TP53 mutations & more

    iwMPN 2025

    27 - 28 June, 2025

  • iwMDS

    Advances in the treatment of LR-MDS: luspatercept combinations, the use of imetelstat & more

    iwMDS 2025

    27 - 29 June, 2025

  • iwMPN

    Novel approaches to upfront management of myelofibrosis

    iwMPN 2025

    27 - 29 June, 2025

  • iwMPN

    Challenging and uncommon scenarios in MPNs

    iwMPN 2025

    27 - 29 June, 2025

  • iwCAR-T

    T-cell engagers and CAR T-cells in R/R CLL: clinical data and future directions

    iwCAR-T 2025

    11 - 13 April, 2025

  • iwCAR-T

    Integrating autoimmune diseases into cellular therapy centers

    iwCAR-T 2025

    11 - 13 April, 2025

  • iwCAR-T

    Translational insights into T-cell engagers and CAR T-cell therapy: targets, the microbiome, & more

    iwCAR-T 2025

    11 - 13 April, 2025

  • iwCAR-T

    CAR-T in ALL: dual targeting strategies, CAR-T in pediatric patients, managing ICANS, and more

    iwCAR-T 2025

    11 - 13 April, 2025

  • iwCAR-T

    T-cell engagers and CARs in myeloid malignancies

    iwCAR-T 2025

    11 - 13 April, 2025

  • iwCAR-T

    Strategies to improve the efficacy and minimize the toxicity of CAR T-cell therapy

    iwCAR-T 2025

    11 - 13 April, 2025

  • iwHRMM

    CAR therapies in high-risk myeloma: current data, their role in high-risk subgroups, & the potential of alloCARs

    iwHRMM 2024

    23 - 25 October, 2024

  • iwHRMM

    Extramedullary disease in multiple myeloma: biology, the potential role of AI, and more

    iwHRMM 2024

    23 - 25 October, 2024

  • iwHRMM

    CTCs in HRMM: their value in diagnosis, prognosis, and guiding treatment decisions

    iwHRMM 2024

    23 - 25 October, 2024

  • iwHRMM

    Bispecific antibodies in the treatment of HRMM: optimizing therapy and combination strategies

    iwHRMM 2024

    23 - 25 October, 2024

  • iwHRMM

    Defining high-risk multiple myeloma: recent advances in the field & future considerations

    iwHRMM 2024

    23 - 25 October, 2024

  • iwAL

    Novel treatments & combinations in AML: mechanisms of resistance to venetoclax & approaching R/R disease

    iwAL 2024

    13 - 15 September, 2024

  • iwAL

    Novel targets, combinations & treatments in AML: use of OGM, TP53 treatment strategies & ADCs

    iwAL 2024

    13 - 15 September, 2024

  • iwAL

    Current data on menin inhibition in AML

    iwAL 2024

    13 - 15 September, 2024

  • iwAL

    Updates on established therapies in AML – Part 2

    iwAL 2024

    13 - 15 September, 2024

  • iwAL

    Updates on established therapies in AML – Part 1

    iwAL 2024

    13 - 15 September, 2024

  • iwAL

    The treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXAS

    iwAL 2024

    13 - 15 September, 2024

  • iwMDS

    Updates in HR-MDS therapies: IDH inhibitors, challenges with transplantation, and more

    iwMDS 2024

    28 - 30 June, 2024

  • iwMDS

    Inflammation & immune interventions in MDS: targeting STAT, IRAK4 & more

    iwMDS 2024

    28 - 30 June, 2024

  • iwMDS

    Updates in the diagnosis, classification & risk stratification of MDS

    iwMDS 2024

    28 - 30 June, 2024

  • iwCAR-T

    CAR T-cells for autoimmune diseases

    iwCAR-T 2024

    19 - 21 April, 2024

  • iwCAR-T

    The future of CAR-T therapy in AML

    iwCAR-T 2024

    19 - 21 April, 2024

  • iwCAR-T

    Allo approaches in CAR-T

    iwCAR-T 2024

    19 - 21 April, 2024

  • iwCAR-T

    An update on CAR-T in CLL

    iwCAR-T 2024

    19 - 21 April, 2024

  • iwMyeloma

    Understanding mechanisms of resistance to targeted therapies in myeloma

    iwMyeloma 2024

    12 - 14 April, 2024

  • IBC Workshop

    Early Interception In SMM & Novel Agents Being Explored

    IBC Workshop 2024

    14 - 16 March, 2024

  • iwNHL

    Updates On The Biology And Treatment Of T-Cell Lymphoma

    iwNHL 2023

    29 September - 1 October, 2023

  • iwAL

    Clonal Hematopoiesis, Early Detection & Potential Therapeutics

    iwAL 2023

    25 - 27 August, 2023

  • iwCAR-T

    CAR-T in AML: updates & challenges

    iwCAR-T 2023

    14 - 16 April, 2023

  • iwMDS

    How can we improve efficiency of drug approval for MDS?

    iwMDS 2022

    24 - 26 June, 2022

Contact Us

If you would like more information, or are interested in supporting one of our on-demand sessions

Get in touch